The integration of artificial intelligence (AI) with nanoparticle technology represents a transformative approach in precision oncology, particularly in the development of targeted anticancer drug delivery systems. In our study, we found out that the application of AI in the field of drug delivery enhances the value of nanoparticles in increasing the efficiency of drug delivery and decreasing side effects from specifically targeted mechanisms. Moreover, we considered urgent issues that exist in present-day nanoparticle fabrication such as scalability and regulatory issues and suggest AI solutions that would help overcome these issues. In the same manner, we focused on the utilization of AI in enhancing patient-centered treatment through the establishment of drug delivery systems that will complement the genetic and molecular makeup of patients. Additionally, we present evidence suggesting that AI-designed nanoparticles have the potential to be environmentally sustainable alternatives in cancer therapy. AI is presented as capable of creating synergies with bioengineering methods like CRISPR or gene therapy and able to show potential directions for enhancing the efficiency of nanoparticle-based cancer therapies. In implementing these findings, we systematically discuss and highlight ongoing work and potential development trends in AI-aided nanoparticle research, asserting that it has the potential to greatly enhance oncology therapy.
Citation: Mujibullah Sheikh, Pranita S. Jirvankar. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology[J]. AIMS Bioengineering, 2024, 11(4): 574-597. doi: 10.3934/bioeng.2024026
The integration of artificial intelligence (AI) with nanoparticle technology represents a transformative approach in precision oncology, particularly in the development of targeted anticancer drug delivery systems. In our study, we found out that the application of AI in the field of drug delivery enhances the value of nanoparticles in increasing the efficiency of drug delivery and decreasing side effects from specifically targeted mechanisms. Moreover, we considered urgent issues that exist in present-day nanoparticle fabrication such as scalability and regulatory issues and suggest AI solutions that would help overcome these issues. In the same manner, we focused on the utilization of AI in enhancing patient-centered treatment through the establishment of drug delivery systems that will complement the genetic and molecular makeup of patients. Additionally, we present evidence suggesting that AI-designed nanoparticles have the potential to be environmentally sustainable alternatives in cancer therapy. AI is presented as capable of creating synergies with bioengineering methods like CRISPR or gene therapy and able to show potential directions for enhancing the efficiency of nanoparticle-based cancer therapies. In implementing these findings, we systematically discuss and highlight ongoing work and potential development trends in AI-aided nanoparticle research, asserting that it has the potential to greatly enhance oncology therapy.
| [1] |
Mitchell MJ, Billingsley MM, Haley RM, et al. (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20: 101-124. https://doi.org/10.1038/s41573-020-0090-8 
|
| [2] |
Prabhakar U, Maeda H, Jain RK, et al. (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research 73: 2412-2417. https://doi.org/10.1158/0008-5472.CAN-12-4561
|
| [3] |
Zhang Y, Wang X (2020) Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol 13: 165. https://doi.org/10.1186/s13045-020-00990-3
|
| [4] |
Malone ER, Oliva M, Sabatini PJB, et al. (2020) Molecular profiling for precision cancer therapies. Genome Med 12: 8. https://doi.org/10.1186/s13073-019-0703-1
|
| [5] |
McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168: 613-628. https://doi.org/10.1016/j.cell.2017.01.018
|
| [6] |
Longo DL (2012) Tumor heterogeneity and personalized medicine. N Engl J Med 366: 956-957. https://doi.org/10.1056/NEJMe1200656
|
| [7] |
Adir O, Poley M, Chen G, et al. (2020) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
|
| [8] |
Shamay Y, Shah J, Işık M, et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17: 361-368. https://doi.org/10.1038/s41563-017-0007-z
|
| [9] |
Adir O, Poley M, Chen G, et al. (2019) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
|
| [10] |
Al-Mohammedawi NA, Zaidan SA, Kashan JS (2024) Bioceramic scaffolds for bone repair and regeneration: a comprehensive review. J Appl Sci Nanotechnol 4: 39-57. https://doi.org/10.53293/jasn.2024.7223.1265
|
| [11] |
Rascio F, Spadaccino F, Rocchetti MT, et al. (2021) The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review. Cancers 13: 3949. https://doi.org/10.3390/cancers13163949
|
| [12] |
Fazio M, Ablain J, Chuan Y, et al. (2020) Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat Rev Cancer 20: 263-273. https://doi.org/10.1038/s41568-020-0252-3
|
| [13] | de Jesus RA, Nascimento VRS, Costa JAS, et al. Empirical modeling, experimental optimization, and artificial intelligence (ANN-GA) as a tool for the efficient dye remediation by the biosilica extracted from sugarcane bagasse ash (2023). https://doi.org/10.1007/s13399-023-04825-2 |
| [14] |
Sun W, Chen G, Du F, et al. (2021) Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches. Curr Stem Cell Re T 16: 367-384. https://doi.org/10.2174/1574888X15999201001204727
|
| [15] |
Lee JK, Liu Z, Sa JK, et al. (2018) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet 50: 1399-1411. https://doi.org/10.1038/s41588-018-0209-6
|
| [16] | Sadr S, Hajjafari A, Rahdar A, et al. (2024) Gold nanobiosensors and Machine Learning: Pioneering breakthroughs in precision breast cancer detection. Eur J Med Chem Rep 12: 100238. https://doi.org/10.1016/j.ejmcr.2024.100238 |
| [17] |
Fathi-karkan S, Shamsabadipour A, Moradi A, et al. (2024) Four-dimensional printing techniques: a comprehensive review of biomedical and tissue engineering developments. BioNanoSci 14: 4189-4218. https://doi.org/10.1007/s12668-024-01596-6
|
| [18] |
Hristova-Panusheva K, Xenodochidis C, Georgieva M, et al. (2024) Nanoparticle-mediated drug delivery systems for precision targeting in oncology. Pharmaceuticals 17: 677. https://doi.org/10.3390/ph17060677
|
| [19] |
Fu X, Shi Y, Qi T, et al. (2020) Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Sig Transduct Target Ther 5: 1-15. https://doi.org/10.1038/s41392-020-00342-0
|
| [20] |
Yao Y, Zhou Y, Liu L, et al. (2020) Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 7: 193. https://doi.org/10.3389/fmolb.2020.00193
|
| [21] |
Siegel RL, Miller KD, Fuchs HE, et al. (2022) Cancer statistics, 2022. CA Cancer J Clin 72: 7-33. https://doi.org/10.3322/caac.21708
|
| [22] |
Wild CP (2019) The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer 19: 123-124. https://doi.org/10.1038/s41568-019-0110-3
|
| [23] |
Elumalai K, Srinivasan S, Shanmugam A (2024) Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Technol 5: 109-122. https://doi.org/10.1016/j.bmt.2023.09.001
|
| [24] |
Mundekkad D, Cho WC (2022) Nanoparticles in clinical translation for cancer therapy. Int J Mol Sci 23: 1685. https://doi.org/10.3390/ijms23031685
|
| [25] |
Hu C-MJ, Aryal S, Zhang L (2010) Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 1: 323-334. https://doi.org/10.4155/tde.10.13
|
| [26] |
Truong NP, Whittaker MR, Mak CW, et al. (2015) The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Del 12: 129-142. https://doi.org/10.1517/17425247.2014.950564
|
| [27] |
Markman M (2006) Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 7: 1469-1474. https://doi.org/10.1517/14656566.7.11.1469
|
| [28] |
Hofheinz R-D, Gnad-Vogt SU, Beyer U, et al. (2005) Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16: 691-707. https://doi.org/10.1097/01.cad.0000167902.53039.5a
|
| [29] |
Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30: 592-599. https://doi.org/10.1016/j.tips.2009.08.004
|
| [30] |
Gubernator J (2011) Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv 8: 565-580. https://doi.org/10.1517/17425247.2011.566552
|
| [31] |
Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. ecancer 13: 961. https://doi.org/10.3332/ecancer.2019.961
|
| [32] |
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765. https://doi.org/10.1056/NEJMoa0804385
|
| [33] |
Di Nicolantonio F, Martini M, Molinari F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712. https://doi.org/10.1200/JCO.2008.18.0786
|
| [34] |
Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Update 29: 90-106. https://doi.org/10.1016/j.drup.2016.10.003
|
| [35] | Gupta N, Hatoum H, Dy GK (2014) First line treatment of advanced non-small-cell lung cancer–specific focus on albumin bound paclitaxel. Int J Nanomed 9: 209-221. https://doi.org/10.2147/IJN.S41770 |
| [36] |
Passero FC, Grapsa D, Syrigos KN, et al. (2016) The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticanc 16: 697-703. https://doi.org/10.1080/14737140.2016.1192471
|
| [37] |
Kim M, Williams S (2018) Daunorubicin and cytarabine liposome in newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. Ann Pharmacother 52: 792-800. https://doi.org/10.1177/1060028018764923
|
| [38] | Raja A, Kasana A, Verma V, et al. Next-generation therapeutic antibodies for cancer treatment: advancements, applications, and challenges (2024). https://doi.org/10.1007/s12033-024-01270-y |
| [39] |
Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. (2024) CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther 31: 667-686. https://doi.org/10.1038/s41417-024-00750-2
|
| [40] |
Harrison TS, Lyseng-Williamson KA (2013) Vincristine sulfate liposome injection. BioDrugs 27: 69-74. https://doi.org/10.1007/s40259-012-0002-5
|
| [41] |
Yang L, Fang H, Jiang J, et al. (2022) EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma. Drug Deliv Transl Res 12: 2527-2536. https://doi.org/10.1007/s13346-021-01094-2
|
| [42] | Raskova Kafkova L, Mierzwicka JM, Chakraborty P, et al. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy (2024). https://doi.org/10.3389/fimmu.2024.1342086 |
| [43] |
Sanchez C, Belleville P, Popall M, et al. (2011) Applications of advanced hybrid organic-inorganic nanomaterials: from laboratory to market. Chem Soc Rev 40: 696-753. https://doi.org/10.1039/c0cs00136h
|
| [44] |
Gao J, Chen K, Miao Z, et al. (2010) Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 32: 2141. https://doi.org/10.1016/j.biomaterials.2010.11.053
|
| [45] |
Sun T, Zhang YS, Pang B, et al. (2014) Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 53: 12320-12364. https://doi.org/10.1002/anie.201403036
|
| [46] |
Kim EM, Jeong HJ (2017) Current status and future direction of nanomedicine: focus on advanced biological and medical applications. Nucl Med Mol Imaging 51: 106-117. https://doi.org/10.1007/s13139-016-0435-8
|
| [47] |
Vijaya Lakshmi K (2023) Artificial intelligence and its applications in nanochemistry. IJETMS 7: 385-389. https://doi.org/10.46647/ijetms.2023.v07i05.046
|
| [48] |
Zhu X, Li Y, Gu N (2023) Application of artificial intelligence in the exploration and optimization of biomedical nanomaterials. Nano Biomed Eng 15: 342-353. https://doi.org/10.26599/NBE.2023.9290035
|
| [49] |
Serrano DR, Luciano FC, Anaya BJ, et al. (2024) Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics 16: 1328. https://doi.org/10.3390/pharmaceutics16101328
|
| [50] |
Chan EM, Xu C, Mao AW, et al. (2010) Reproducible, high-throughput synthesis of colloidal nanocrystals for optimization in multidimensional parameter space. Nano Lett 10: 1874-1885. https://doi.org/10.1021/nl100669s
|
| [51] |
Kajita S, Ohba N, Suzumura A, et al. (2020) Discovery of superionic conductors by ensemble-scope descriptor. NPG Asia Mater 12: 1-8. https://doi.org/10.1038/s41427-020-0211-1
|
| [52] |
Yamankurt G, Berns EJ, Xue A, et al. (2019) Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng 3: 318-327. https://doi.org/10.1038/s41551-019-0351-1
|
| [53] |
Yuan M, Kermanian M, Agarwal T, et al. (2023) Defect engineering in biomedical sciences. Adv Mater 35: 2304176. https://doi.org/10.1002/adma.202304176
|
| [54] |
Wu Y, Duan H, Xi H (2020) Machine learning-driven insights into defects of zirconium metal–organic frameworks for enhanced ethane–ethylene separation. Chem Mater 32: 2986-2997. https://doi.org/10.1021/acs.chemmater.9b05322
|
| [55] |
Li S, Barnard AS (2022) Inverse design of nanoparticles using multi-target machine learning. Adv Theor Simul 5: 2100414. https://doi.org/10.1002/adts.202100414
|
| [56] |
Thomas DG, Chikkagoudar S, Heredia-Langner A, et al. (2014) Physicochemical signatures of nanoparticle-dependent complement activation. Comput Sci Discov 7: 015003. https://doi.org/10.1088/1749-4699/7/1/015003
|
| [57] |
Boso DP, Lee S-Y, Ferrari M, et al. (2011) Optimizing particle size for targeting diseased microvasculature: from experiments to artificial neural networks. IJN 6: 1517-1526. https://doi.org/10.2147/IJN.S20283
|
| [58] |
Galasso I, Erikainen S, Pickersgill M, et al. (2024) “Different names for the same thing”? novelty, expectations, and performative nominalism in personalized and precision medicine. Soc Theory Health 22: 139-155. https://doi.org/10.1057/s41285-024-00203-8
|
| [59] |
Schleidgen S, Klingler C, Bertram T, et al. (2013) What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 14: 55. https://doi.org/10.1186/1472-6939-14-55
|
| [60] |
Delpierre C, Lefèvre T (2023) Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health. Front Sociol 8: 1112159. https://doi.org/10.3389/fsoc.2023.1112159
|
| [61] |
Das KP, J C (2023) Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: current progress and challenges. Front Med Technol 4: 1067144. https://doi.org/10.3389/fmedt.2022.1067144
|
| [62] |
Wang J, Liu G, Zhou C, et al. (2024) Application of artificial intelligence in cancer diagnosis and tumor nanomedicine. Nanoscale 16: 14213-14246. https://doi.org/10.1039/D4NR01832J
|
| [63] |
Majumder J, Taratula O, Minko T (2019) Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliver Rev 144: 57. https://doi.org/10.1016/j.addr.2019.07.010
|
| [64] |
Yook S, Cai Z, Lu Y, et al. (2015) Radiation nanomedicine for EGFR-positive breast cancer: panitumumab-modified gold nanoparticles complexed to the β-particle-emitter, (177)Lu. Mol Pharm 12: 3963-3972. https://doi.org/10.1021/acs.molpharmaceut.5b00425
|
| [65] |
Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56: 226-243. https://doi.org/10.3322/canjclin.56.4.226
|
| [66] |
Adir O, Poley M, Chen G, et al. (2019) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater 32: e1901989. https://doi.org/10.1002/adma.201901989
|
| [67] | Ori MO, Ekpan FM, Samuel HS, et al. (2024) Integration of artificial intelligence in nanomedicine. Eurasian J Sci Technol 4: 88-104. https://doi.org/10.48309/EJST.2024.422419.1105 |
| [68] |
Medhi B, Sharma DH, Kaundal DT, et al. (2024) Artificial intelligence: a catalyst for breakthroughs in nanotechnology and pharmaceutical research. IJPSN 17: 7439-7445. https://doi.org/10.37285/ijpsn.2024.17.4.1
|
| [69] |
Gawel AM, Betkowska A, Gajda E, et al. (2024) Current non-metal nanoparticle-based therapeutic approaches for glioblastoma treatment. Biomedicines 12: 1822. https://doi.org/10.3390/biomedicines12081822
|
| [70] |
Qi G, Shi G, Wang S, et al. (2023) A novel pH-responsive Iron oxide core-shell magnetic mesoporous Silica nanoparticle (M-MSN) system encapsulating doxorubicin (DOX) and glucose oxidase (Gox) for pancreatic cancer treatment. Int J Nanomed 18: 7133-7147. https://doi.org/10.2147/IJN.S436253
|
| [71] |
Choi KY, Liu G, Lee S, et al. (2012) Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4: 330-342. https://doi.org/10.1039/C1NR11277E
|
| [72] |
Ristau BT, O'Keefe DS, Bacich DJ (2014) The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 32: 272-279. https://doi.org/10.1016/j.urolonc.2013.09.003
|
| [73] | Ciccarese C, Bauckneht M, Zagaria L, et al. (2024) Defining the position of [177Lu] Lu-PSMA radioligand therapy in the treatment landscape of metastatic castration-resistant prostate cancer: a meta-analysis of clinical trials. Targ Oncol 2024: 1-10. https://doi.org/10.1007/s11523-024-01117-1 |
| [74] |
Von Hoff DD, Mita MM, Ramanathan RK, et al. (2016) Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res 22: 3157-3163. https://doi.org/10.1158/1078-0432.CCR-15-2548
|
| [75] |
Ni J, Miao T, Su M, et al. (2021) PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases. J Control Release 329: 934-947. https://doi.org/10.1016/j.jconrel.2020.10.023
|
| [76] |
Autio KA, Garcia JA, Alva AS, et al. (2016) A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). JCO 34: 233-233. https://doi.org/10.1200/jco.2016.34.2_suppl.233
|
| [77] | Bakht MK, Beltran H (2024) Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol 2024: 1-20. https://doi.org/10.1038/s41585-024-00900-z |
| [78] |
Zahednezhad F, Allahyari S, Sarfraz M, et al. (2024) Liposomal drug delivery systems for organ-specific cancer targeting: early promises, subsequent problems, and recent breakthroughs. Expert Opinion Drug Del 21: 1363-1384. https://doi.org/10.1080/17425247.2024.2394611
|
| [79] |
Rizwanullah M, Ahmad MZ, Ghoneim MM, et al. (2021) Receptor-mediated targeted delivery of surface-modifiednanomedicine in breast cancer: recent update and challenges. Pharmaceutics 13: 2039. https://doi.org/10.3390/pharmaceutics13122039
|
| [80] |
Guddo F, Giatromanolaki A, Koukourakis MI, et al. (1998) MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 51: 667-671. https://doi.org/10.1136/jcp.51.9.667
|
| [81] |
Wurz GT, Kao CJ, Wolf M, et al. (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vacc Immunother 10: 3383-3393. https://doi.org/10.4161/hv.29836
|
| [82] |
Cats A, Jansen EPM, Grieken NCT van, et al. (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19: 616-628. https://doi.org/10.1016/S1470-2045(18)30132-3
|
| [83] |
Sabir F, Qindeel M, Zeeshan M, et al. (2021) Onco-receptors targeting in lung cancer via application of surface-modified and hybrid nanoparticles: a cross-disciplinary review. Processes 9: 621. https://doi.org/10.3390/pr9040621
|
| [84] |
Hoshyar N, Gray S, Han H, et al. (2016) The effect of nanoparticle size on In Vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 11: 673-692. https://doi.org/10.2217/nnm.16.5
|
| [85] |
Zrazhevskiy P, Sena M, Gao X (2010) Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem Soc Rev 39: 4326. https://doi.org/10.1039/b915139g
|
| [86] |
Singh P, Pandit S, Mokkapati VRSS, et al. (2018) Gold nanoparticles in diagnostics and therapeutics for human cancer. IJMS 19: 1979. https://doi.org/10.3390/ijms19071979
|
| [87] |
Kim D, Jeong YY, Jon S (2010) A drug-loaded aptamer–gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4: 3689-3696. https://doi.org/10.1021/nn901877h
|
| [88] |
Wilson K, Homan K, Emelianov S (2012) Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging. Nat Commun 3: 618. https://doi.org/10.1038/ncomms1627
|
| [89] |
Dias R, Torkamani A (2019) Artificial intelligence in clinical and genomic diagnostics. Genome Med 11: 70. https://doi.org/10.1186/s13073-019-0689-8
|
| [90] |
Aung KL, Fischer SE, Denroche RE, et al. (2018) Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res 24: 1344-1354. https://doi.org/10.1158/1078-0432.CCR-17-2994
|
| [91] |
Rao W, Wang H, Han J, et al. (2015) Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 9: 5725-5740. https://doi.org/10.1021/nn506928p
|
| [92] |
Senapati S, Mahanta AK, Kumar S, et al. (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Sig Transduct Target Ther 3: 7. https://doi.org/10.1038/s41392-017-0004-3
|
| [93] |
Xu Y, Hosny A, Zeleznik R, et al. (2019) Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res 25: 3266-3275. https://doi.org/10.1158/1078-0432.CCR-18-2495
|
| [94] | Sun Z, Song C, Wang C, et al. (2020) Hydrogel-based controlled drug delivery for cancer treatment: a review. Mol Pharmaceutics 17: 373-391. https://doi.org/10.1021/acs.molpharmaceut.9b01020 |
| [95] |
Sykes EA, Dai Q, Sarsons CD, et al. (2016) Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci USA 113: E1142-E1151. https://doi.org/10.1073/pnas.1521265113
|
| [96] |
Bhinder B, Gilvary C, Madhukar NS, et al. (2021) Artificial intelligence in cancer research and precision medicine. Cancer Discov 11: 900-915. https://doi.org/10.1158/2159-8290.CD-21-0090
|
| [97] |
Zhang Y, Lin R, Li H, et al. (2019) Strategies to improve tumor penetration of nanomedicines through nanoparticle design. WIREs Nanomed Nanobiotechnol 11: e1519. https://doi.org/10.1002/wnan.1519
|
| [98] |
Keith JA, Vassilev-Galindo V, Cheng B, et al. (2021) Combining machine learning and computational chemistry for predictive insights into chemical systems. Chem Rev 121: 9816-9872. https://doi.org/10.1021/acs.chemrev.1c00107
|
| [99] |
Kennedy LC, Bickford LR, Lewinski NA, et al. (2011) A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 7: 169-183. https://doi.org/10.1002/smll.201000134
|
| [100] |
Merino S, Martín C, Kostarelos K, et al. (2015) Nanocomposite hydrogels: 3D polymer–nanoparticle synergies for on-demand drug delivery. ACS Nano 9: 4686-4697. https://doi.org/10.1021/acsnano.5b01433
|
| [101] |
Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. IJN 2012: 5577-5591. https://doi.org/10.2147/IJN.S36111
|
| [102] | AI FORM: An AI-Driven Platform for Acceleration of Nanomedicine Development Science Foundation Ireland. Available from: https://www.sfi.ie/challenges/future-digital/ai-form/ |
| [103] | The Power of AI-Generated Nanoparticles in Targeted Drug DeliveryNano Magazine - Latest Nanotechnology News (2023). Available from: https://nano-magazine.com/news/2023/7/3/the-power-of-ai-generated-nanoparticles-in-targeted-drug-delivery |
| [104] |
Greenberg ZF, Graim KS, He M (2023) Towards artificial intelligence-enabled extracellular vesicle precision drug delivery. Adv Drug Deliver Rev 199: 114974. https://doi.org/10.1016/j.addr.2023.114974
|
| [105] | Weerarathna IN, Kamble AR, Luharia A (2023) Artificial intelligence applications for biomedical cancer research: a review. Cureus 15: e48307. https://doi.org/10.7759/cureus.48307 |
| [106] |
Chugh V, Basu A, Kaushik A, et al. (2024) Employing nano-enabled artificial intelligence (AI)-based smart technologies for prediction, screening, and detection of cancer. Nanoscale 16: 5458-5486. https://doi.org/10.1039/D3NR05648A
|
| [107] |
Liu J, Du H, Huang L, et al. (2024) AI-powered microfluidics: shaping the future of phenotypic drug discovery. ACS Appl Mater Interfaces 16: 38832-38851. https://doi.org/10.1021/acsami.4c07665
|
Figures(4) / Tables(2)
Mujibullah Sheikh, Pranita S. Jirvankar. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology[J]. AIMS Bioengineering, 2024, 11(4): 574-597. doi: 10.3934/bioeng.2024026
DownLoad: